Bruno Vellas
Bruno Vellas
Cost analyses of plasma p-tau217 versus p-tau217/Aβ42 ratio using two-step approach in the Japanese health care system [0.03%]
Masanori Kurihara,Ryoko Ihara,Kenichiro Sato et al.
Masanori Kurihara et al.
Plasma p-tau217 may offer a cost-saving effect in diagnosing Alzheimer's disease. However, each healthcare system has different costs, and its impact on evaluating anti-amyloid β (Aβ) therapies in Japan remains unclear. We conducted cost ...
Zheng-Bin Liao,Zi-Cheng Hu,Gui-Hua Zeng et al.
Zheng-Bin Liao et al.
Background: While omega-3 fatty acid supplementation is widely used for cognitive protection, its efficacy remains controversial, and its impact on core Alzheimer's disease (AD) pathologies in humans is not well-establish...
Speech-based digital biomarkers for early etiological stratification of Alzheimer's disease and frontotemporal degeneration: a biomarker-confirmed prospective study [0.03%]
Eloïse Da Cunha,Valeria Manera,Frédéric Chorin et al.
Eloïse Da Cunha et al.
Background: Early differentiation between Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD) is a prerequisite for secondary prevention and targeted trial enrollment, yet remains challenging at disease ...
Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control data [0.03%]
Bjoern O Schelter,Helen Shiells,Serena Lo et al.
Bjoern O Schelter et al.
Background: Hydromethylthionine mesylate (HMTM) targets tau pathology and also has tau-independent symptomatic activity. A traditional randomised placebo-controlled trial (RCT) was precluded by loss of blinding due to uri...
The concurrent burden of Alzheimer's pathology, cerebral amyloid angiopathy, and microinfarcts on cognitive decline [0.03%]
Mingyao You,Chao Tang,Lianfei Liu et al.
Mingyao You et al.
Background: Alzheimer's disease (AD) is frequently complicated by vascular co-morbidities. However, the specific mechanistic pathways by which vascular lesions interact with genetic susceptibility to accelerate cognitive ...
Pathways to participation - a scoping review outlining barriers and enablers to participation in dementia research [0.03%]
参与痴呆症研究的途径-概述参与障碍和促进因素的综述性评论文章
Lukas A Duffner,Soraya Moradi-Bachiller,Dianne Gove et al.
Lukas A Duffner et al.
Background: Ongoing participant recruitment challenges in dementia research highlight the need to understand public perspectives on research participation. This scoping review explored existing literature on barriers and ...
Hypolipidemics reduce the rate of Alzheimer's disease development and dementia progression: A cohort study linked with genetic and neuropathological analyses [0.03%]
降脂药减缓阿尔茨海默病的发生和发展速度及痴呆的进展：一项与遗传学和神经病理学分析相联系的队列研究
Zohi Sternberg,Rebecca E Podolsky,Jihnhee Yu et al.
Zohi Sternberg et al.
Background: High cholesterol contributes to the development and progression of dementia due to both Alzheimer's disease (A.D.) and vascular pathology. However, the effects of lipid-lowering regimen (LLR) on cognitive dysf...
ATNIVS biomarker heterogeneity in real-world patients receiving lecanemab [0.03%]
接受莱卡单抗治疗的现实世界患者的ATN和Cerebrovascular淀粉样蛋白生物标志物异质性
Masanori Kurihara,Ryoko Ihara,Gen Yoshii et al.
Masanori Kurihara et al.
Background: While amyloid-β (Aβ) biomarker positivity is sufficient before initiating anti-Aβ antibody therapy, recent revised criteria also highlight the importance of other biomarkers (ATNIVS) to understand heterogen...
Gregory Cooper
Gregory Cooper